Leap Therapeutics Announces Closing of Previously Announced Equity Financing
Summary
The holder of Series A mandatorily convertible preferred stock also received a share of a newly designated special voting preferred stock that will entitle it to elect one member of Leaps Board of Directors. The aggregate gross proceeds to Leap from this offering are approximately , before deducting placement agent fees and estimated offering expenses payable by Leap, and excluding proceeds from the exercise of any warrants. Leaps most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein, a Wnt pathway modulator. Such risks and uncertainties include, but are not limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in periodic filings with the , including Leaps Annual Report on Form 10-K for the fiscal year ended , as filed with the on , and Leaps Quarterly Reports on Form 10-Q.